A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
OHSU Knight Cancer Institute
National Institutes of Health Clinical Center (CC)
Incyte Corporation
NGM Biopharmaceuticals, Inc
National Cancer Institute (NCI)
Cyteir Therapeutics, Inc.
Eli Lilly and Company
Northwestern University
Masonic Cancer Center, University of Minnesota
Altor BioScience
Dartmouth-Hitchcock Medical Center